Psoriasis can be defined as an unstable state of epidermal growth in certain areas of the body. This is not a real disease, but rather an anomaly in the growth of the epidermis, which can appear and disappear spontaneously. Among the forms in which it occurs there is also the “plaque” one in which the skin lesions are formed by red plaques, in relief and covered by silvery-white desquamations that come off regularly. These can cause itching and burning and, if irritated, can also lead to bleeding. In the context of treatment against moderate to severe plaque psoriasis, an oral drug, Deucravacitinib, a specific inhibitor that acts on a particular molecule involved in the disease, has been confirmed to be safe and effective in the long term. This was confirmed by the pharmaceutical company Bristol Myers Squibb.
The results of the study
deepening
Psoriasis, 2 million Italians suffer from it: novelties in therapies
The drug, which is currently undergoing regulatory review in several parts of the world, including the United States, Europe and Japan and could be the first selective tyrosine kinase 2 inhibitor approved for clinical use, has been the focus of a study. long-term, referred to as “POETYK PSO LTE”. As reported by Bristol Myers Squibb in a note, Deucravacitinib has provided good results, in terms of efficacy, showing that it can work over time. Clinical efficacy was maintained for two years of therapy, the experts explained, with response rates at week 60 of 77.7% and 58.7% based on two ad hoc rating scales for the patients involved. . These data, among other things, were also presented during the European Academy of Dermatology (EADV) Spring Symposium, held a few days ago.
The potential of the oral drug
According to Richard Warren, consultant dermatologist at Salford Royal Hospital, England, part of the Northern Care Alliance NHS Foundation Trust, “Plaque psoriasis is a chronic immune-mediated disease associated with multiple serious comorbidities and with the need for new therapies, in particular of oral medications, as many patients are not treated adequately or are dissatisfied with current treatment options ”. Now, also thanks to the new data emerging from this two-year study, it was possible to underline “the potential of Deucravacitinib as an important new treatment option for patients with moderate to severe plaque psoriasis requiring systemic therapy”.